The Challenge of Delivering Gene Therapy:
Roadblock to Progress
While the potential of gene therapy and genomic engineering to improve human life is immense, a significant obstacle has hindered its progress: the lack of safe and effective delivery systems to convey gene-editing agents to the desired organs.
Current limitations:
Viral Vectors:
While very effective in delivering genetic material, viral vectors carry inherent safety risks. Clinical trials have borne out these dangers, with instances of severe adverse effects and even patient fatalities.
Non-Viral Vectors:
Cationic lipids and their nanoparticle derivatives, despite showing promise in vitro and in animal studies, have fallen short in human trials. Their clinical deployment has been marred by toxic effects, immunogenicity, and/or inefficient transduction of organs beyond the liver and the lungs.
potential impact
The potential impact of this technology is vast:
Enhanced Quality of Life:
By enabling targeted genetic interventions in muscles, this technology could improve quality of life for individuals suffering from muscle-related diseases and age-related decline.
Explore More 
Athletic Performance:
The ability to modify muscle function could also open doors for enhancing athletic performance and recovery.
Explore More
Healthy Aging:
Addressing muscle atrophy could significantly improve the health and independence of the elderly population.
Explore More
A Novel Solution:
Fusogen-Based Nanoparticles with Intrinsic Muscle Tropism
Bromios Biotechnologies is at the forefront of developing a revolutionary solution to the gene delivery challenge: a new class of nanoparticles incorporating fusogenic proteins with intrinsic tissue affinity for skeletal muscles. These proteins promote the direct fusion of nanoparticles with the target cell membranes. Transduction efficiency is vastly improved over traditional lipid vectors, because the primary hurdle to cell entry (endocytosis and subsequent escape from the endosomal compartment) is bypassed altogether. Additionally, the fusogen shows innate binding affinity for myofibers, causing diffuse transduction of skeletal muscles.
This unique tropism has great potential to enhance human health:
Strength and Metabolism:
Skeletal muscles comprise 40% of an adult's body weight and play the main role in mobility, strength, and metabolic function. Genetic enhancement in these areas is likely to have major consequences for quality of life.
Impact of Aging:
Age-related muscle atrophy is a major contributor to disability, loss of independence, and mortality of the elderly due to falls. Preventing this decay by gene-editing interventions could substantially ease the burden of old age.
Genetic muscle disorders:
Myopathies and dystrophies affect a significant number of people, with estimates reaching up to 100,000 individuals in the United States alone. Correcting the underlying genetic defect is the ultimate goal of therapy for these individuals.